Revelation Biosciences, Inc.
REVB
$1.01
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.64% | 6.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.42% | 20.26% | |||
| Operating Income | -18.42% | -20.26% | |||
| Income Before Tax | -10.44% | -19.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.44% | -19.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.44% | -19.84% | |||
| EBIT | -18.42% | -20.26% | |||
| EBITDA | -18.43% | -20.25% | |||
| EPS Basic | 67.97% | -64.44% | |||
| Normalized Basic EPS | 7.49% | 43.07% | |||
| EPS Diluted | 67.97% | -64.44% | |||
| Normalized Diluted EPS | 7.49% | 43.07% | |||
| Average Basic Shares Outstanding | 19.38% | 110.48% | |||
| Average Diluted Shares Outstanding | 19.38% | 110.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||